Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 5.8% – What’s Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares traded up 5.8% during mid-day trading on Thursday . The stock traded as high as $14.70 and last traded at $14.70. 36,400 shares were traded during mid-day trading, a decline of 95% from the average session volume of 751,431 shares. The stock had previously closed at $13.90.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $20.83.

Stoke Therapeutics Price Performance

The firm has a market cap of $747.89 million, a PE ratio of -6.62 and a beta of 0.95. The stock’s fifty day moving average price is $13.14 and its 200-day moving average price is $13.77.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. On average, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 11.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds have recently modified their holdings of the company. Assenagon Asset Management S.A. acquired a new position in Stoke Therapeutics in the second quarter valued at about $19,835,000. SG Americas Securities LLC lifted its position in shares of Stoke Therapeutics by 610.3% during the second quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock worth $927,000 after purchasing an additional 58,943 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Stoke Therapeutics by 4.1% during the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock worth $23,160,000 after purchasing an additional 67,052 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after purchasing an additional 1,123,500 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in Stoke Therapeutics by 528.6% in the second quarter. Millennium Management LLC now owns 289,067 shares of the company’s stock valued at $3,905,000 after acquiring an additional 243,083 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.